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CORRECTION Open Access
Correction to: Efficacy of Ronopterin
(VAS203) in Patients with Moderate and
Severe Traumatic Brain Injury (NOSTRA
phase III trial): study protocol of a
confirmatory, placebocontrolled,
randomised, double blind, multi-centre
study
Frank Tegtmeier1, Reinhard Schinzel1*, Ronny Beer2, Diederik Bulters3, Jean-Yves LeFrant4, Joan Sahuquillo5,
Andreas Unterberg6, Peter Andrews7, Antonio Belli8, Javier Ibanez9, Alfonso Lagares10, Michael Mokry11,
Harald Willschke12, Charlotte Flüh13, Erich Schmutzhard2 and on behalf of the NOSTRA Investigators
Correction to: Trials (2020) 21:80
https://doi.org/10.1186/s13063-019-3965-4
After publication of our article [1] the authors have
notified us that one of the names has been incorrectly
spelled.
 Original name spelling:
Charlotte Flühe
 Correct name spelling:
Charlotte Flüh
The original article has been corrected.
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